Silexion Therapeutics Corp, a Cayman Islands-based company, announced on May 22, 2025, that it received a delisting notice from the Nasdaq Listing Qualifications Department. The notice pertains to the company's failure to comply with Nasdaq Listing Rules 5450(b)(2)$(A)$ and 5450(b)(2)$(C)$, which require maintaining a minimum Market Value of Listed Securities of $50 million and a Market Value of Publicly Held Shares of $15 million. Despite a 180-day compliance period ending May 19, 2025, Silexion was unable to rectify these deficiencies. The company plans to appeal the decision before the Nasdaq Hearings Panel by May 29, 2025. If the appeal is unsuccessful, trading of its shares and warrants will be suspended on June 2, 2025, and a Form 25-NSE will be filed with the SEC to remove its securities from Nasdaq listing. Additionally, Silexion intends to apply for a transfer to the Nasdaq Capital Market, contingent upon meeting the required Equity Standard.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。